Multiple Sclerosis [MS], as we know it, is an autoimmune disease that results in the slowing of the speed of signals sent from the central nervous system to the peripheral nervous system and can even result in irreversible damage to the nerves in the central nervous system that were once protected by the myelin sheath. This condition can leave a patient suffering from a wide range of symptoms including fatigue, depression, weakness, spasms, spasticity, pain, sleep disturbances and more.
One of the largest studies on the effect of medical cannabis on patients with MS stated that patients who used Tetrahydrocannabinol reported improvements in pain, sleep quality, spasms and spasticity.
There is even evidence that suggests that cannabinoids may have immunomodulatory effects, and have therapeutic benefits in treating MS. 1
Current studies show that patients who perceive initial benefits from their cannabis medication experienced persisting positive effects into extended trials without tolerance.
Of a small group of MS patients who participated in an abrupt interruption of their cannabis medication, there was no consistent withdrawal symptoms and five patients had to resume taking their medication due to reemergence of symptoms.
Symptomatic medications often do not provide adequate relief and may have toxic effects that can worsen a patient’s already diminished quality of life.1 These effects can be weighed in comparison to cannabis’s relatively limited side effects.
For more information on research studies relating to cannabis click here.
 Hazekamp, Arno, and Franjo Grotenhermen. “Review on Clinical Studies with Cannabis and Cannabinoids 2005-2009.” 5.Special Issue (2010): 1-21. Print.